A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small …
KL Reckamp, G Giaccone, DR Camidge, SM Gadgeel… - Cancer, 2014 - Wiley Online Library
BACKGROUND This phase 2 trial (ClinicalTrials. gov identifier NCT00548093) assessed the
efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) …
efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) …
[HTML][HTML] A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non …
KL Reckamp, G Giaccone, DR Camidge, SM Gadgeel… - Cancer, 2014 - ncbi.nlm.nih.gov
METHODS Patients with advanced NSCLC, progression on 1 or 2 regimens of
chemotherapy and erlotinib, KRAS wild‐type or known EGFR‐sensitizing mutant tumor, and …
chemotherapy and erlotinib, KRAS wild‐type or known EGFR‐sensitizing mutant tumor, and …
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small …
KL Reckamp, G Giaccone, DR Camidge, SM Gadgeel… - Cancer, 2014 - europepmc.org
Background This phase 2 trial (ClinicalTrials. gov identifier NCT00548093) assessed the
efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an …
efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an …
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small …
KL Reckamp, G Giaccone, DR Camidge… - Cancer, 2014 - pubmed.ncbi.nlm.nih.gov
Background This phase 2 trial (ClinicalTrials. gov identifier NCT00548093) assessed the
efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an …
efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an …
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small …
KL Reckamp, G Giaccone, DR Camidge… - Cancer …, 2014 - search.ebscohost.com
BACKGROUND This phase 2 trial (identifier NCT00548093) assessed the efficacy, safety,
and impact on health-related quality of life of dacomitinib (PF-00299804), an irreversible …
and impact on health-related quality of life of dacomitinib (PF-00299804), an irreversible …
[引用][C] A Phase 2 Trial of Dacomitinib (PF-00299804), an Oral, Irreversible Pan-HER (Human Epidermal Growth Factor Receptor) Inhibitor, in Patients With Advanced …
KL RECKAMP, G GIACCONE, A RUIZ-GARCIA… - Cancer, 2014 - pascal-francis.inist.fr
A Phase 2 Trial of Dacomitinib (PF-00299804), an Oral, Irreversible Pan-HER (Human Epidermal
Growth Factor Receptor) Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer After …
Growth Factor Receptor) Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer After …
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small …
KL Reckamp, G Giaccone, DR Camidge, SM Gadgeel… - Cancer, 2014 - infona.pl
BACKGROUND This phase 2 trial (ClinicalTrials. gov identifier NCT00548093) assessed the
efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) …
efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) …
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small …
KL Reckamp, G Giaccone, DR Camidge, SM Gadgeel… - Cancer, 2014 - hero.epa.gov
BACKGROUND: This phase 2 trial (ClinicalTrials. gov identifier NCT00548093) assessed
the efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804) …
the efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804) …